Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > They closed $3 million
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(82)
•••
Comment by fatboy92on Jun 29, 2021 10:57pm
129 Views
Post# 33471337

RE:RE:RE:RE:RE:They closed $3 million

RE:RE:RE:RE:RE:They closed $3 million Beenthere u dumb (stockhouse won't let me put my actual words here) Lind Partners could buy on the open market but BTI wouldn't receive a penny of it. Could you ever see the bright side of anything. I can't wait for you too sell your shares and move on and hopefully BTI makes a huge move after your gone. Then you can tell everyone on the next company bullboard you buy shares in how wise you are and what a fraud management is and how the biggest supporters of the company are all in on this massive scam that corporations are playing on you and your friends...please stay away, on behalf of myself and anyone else who has my sentiments. Ps...Lind Partners can and do buy shares in the open market, if you ever cared to read past the first sentence before outrage hit your simple mind....
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities